IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) chief scientific and medical officer Robin Wolz tells Proactive's Stephen Gunnion that three internationally recognised specialists have joined the company's Scientific Advisory Board — two in Alzheimer's disease and one in Parkinson's — as the company deepens its position in neurodegenerative disease research.
A new collaboration with the Paris Brain Institute will focus on next-generation MRI biomarkers for Parkinson's, while two IXICO scientists have been invited to contribute to the Michael J. Fox Foundation's MRI Advisory Committee.
Wolz is direct about why the appointments matter: "Having them in our advisory board helps ensure that the biomarkers and approaches we're developing remain scientifically rigorous, clinically relevant and most importantly, aligned with the needs of drug developers." With Alzheimer's and Parkinson's drug pipelines expanding rapidly, demand for reliable imaging biomarkers to support clinical trials has never been higher.
Watch the full interview to learn how IXICO is expanding its scientific ecosystem and supporting the development of next-generation treatments for neurodegenerative diseases.
For more videos from Proactive, visit the Proactive YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications so you never miss future content.
#IXICO #RobinWolz #AlzheimersDisease #ParkinsonsDisease #Neuroscience #Biomarkers #MRI #MedicalImaging #ArtificialIntelligence #DrugDevelopment #ClinicalTrials #NeurodegenerativeDisease #Biotech #HealthcareInnovation #ParisBrainInstitute #MichaelJFoxFoundation
